{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:59:37Z","timestamp":1790323177117,"version":"4.1.0"},"reference-count":124,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Drug resistance remains a major barrier to durable targeted therapy, and cancer progression often reflects rewiring of signalling pathways that control protein stability. Dysregulation of the ubiquitin\u2013proteasome system, including failure of degron-dependent substrate recognition, can stabilise oncogenic proteins, accelerate tumour-suppressor loss and generate treatment-dependent protein states. Yet clinical interpretation commonly relies on genotype or steady-state abundance, neither of which directly identifies the degradation rate or route of a specific substrate. In this critical narrative review, we use cancer degronopathy as a restricted operational term for tumour-relevant alterations in degron-dependent recognition, rather than as an established disease or diagnostic class. Through contrastive analysis of four endogenous modules (SPOP; FBXW7 versus CTNNB1; KEAP1\u2013NFE2L2\u2013CUL3; and VHL\u2013HIF), together with drug-induced degradation, we examine how altered protein fate intersects with signalling pathways implicated in cancer progression, intrinsic or acquired drug resistance and therapeutic response. We trace each candidate biomarker from the initiating tumour event and substrate-specific fate change to patient-compatible measurement, analytical performance and intended clinical use. The analysis shows that SPOP effects vary with allele, substrate, lineage and assembly; FBXW7 reader defects and CTNNB1 cis-acting escape require different analytes; and pooled KEAP1-axis states and cross-isoform VHL\u2013HIF extrapolations remain unresolved. Pharmacological degradation adds a temporal layer: vepdegestrant acts through oestrogen receptor-\u03b1 degradation, whereas its FDA-authorised companion diagnostic selects patients by plasma ESR1 genotype, and serial target measurements are required to distinguish productive target loss, failed loss, recovery and downstream escape. Protein-fate measurement may be informative if it resolves a reproducible, decision-relevant state that genotype, abundance or pathway-output markers leave ambiguous. We define the experimental and clinical evidence needed to test whether such measurements can inform precision strategies to address drug resistance and cancer progression. Conclusion remain limited to the contrastive cases and United States records reviewed through 26 July 2026, with separately dated updates to selected trial records.<\/jats:p>","DOI":"10.3389\/fcell.2026.1960932","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:09:00Z","timestamp":1790320140000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer degronopathies and protein-fate biomarkers in drug resistance and cancer progression: signalling mechanisms, measurement and translational limits"],"prefix":"10.3389","volume":"14","author":[{"given":"Jiaxin","family":"Li","sequence":"first","affiliation":[{"name":"The First Operating Room, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhan","family":"Liu","sequence":"additional","affiliation":[{"name":"The First Operating Room, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Fu","sequence":"additional","affiliation":[{"name":"Clinical Medical College, Changchun University of Traditional Chinese Medicine","place":["Changchun, Jilin, China"]},{"name":"Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifu","family":"Bo","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Oncology, Affiliated Hospital of Shandong Second Medical University","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangpeng","family":"Dai","sequence":"additional","affiliation":[{"name":"Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, The First Hospital of Jilin University","place":["Changchun, China"]},{"name":"National-Local Joint Engineering Laboratory of Animal Models for Human Disease, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nbt.1546","article-title":"Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma","volume":"27","author":"Addona","year":"","journal-title":"Nat. Biotechnol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nbt0909-864b","article-title":"Corrigendum: multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma","volume":"27","author":"Addona","year":"","journal-title":"Nat. Biotechnol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"101104","DOI":"10.1016\/j.crmeth.2025.101104","article-title":"Deuterium labeling enables proteome-wide turnover kinetics analysis in cell culture","volume":"5","author":"Alamillo","year":"2025","journal-title":"Cell Rep. Methods"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1101\/gad.230302","article-title":"Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway","volume":"16","author":"Amit","year":"2002","journal-title":"Genes Dev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.celrep.2014.01.013","article-title":"Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants","volume":"6","author":"An","year":"2014","journal-title":"Cell Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ng.2279","article-title":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer","volume":"44","author":"Barbieri","year":"2012","journal-title":"Nat. Genet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"B8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41698-026-01517-8","article-title":"Mass spectrometry-based proteomics delivers in-depth proteome profiling of FFPE lung cancer biopsies from single glass slides","volume":"10","author":"Berkovska","year":"2026","journal-title":"NPJ Precis. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.molcel.2018.08.027","article-title":"Cancer mutations of the tumor suppressor SPOP disrupt the formation of active, phase-separated compartments","volume":"72","author":"Bouchard","year":"2018","journal-title":"Mol. Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","year":"2013","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7568","DOI":"10.1016\/j.cell.2024.10.012","article-title":"Recognition of BACH1 quaternary structure degrons by two F-box proteins under oxidative stress","volume":"187","author":"Cao","year":"2024","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1074\/mcp.M113.036095","article-title":"Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach","volume":"13","author":"Carr","year":"2014","journal-title":"Mol. Cell Proteomics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus everolimus for advanced renal-cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa2518245","article-title":"Adjuvant pembrolizumab plus belzutifan for renal-cell carcinoma","volume":"395","author":"Choueiri","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1038\/onc.2012.388","article-title":"Nrf2 is controlled by two distinct \u03b2-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity","volume":"32","author":"Chowdhry","year":"2013","journal-title":"Oncogene"},{"key":"B17","doi-asserted-by":"publisher","first-page":"12673","DOI":"10.1038\/ncomms12673","article-title":"Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases","volume":"7","author":"Chowdhury","year":"2016","journal-title":"Nat. Commun."},{"key":"B18","unstructured":"KEAPSAKE: a study of telaglenastat with standard-of-care chemoimmunotherapy in first-line KEAP1\/NRF2-mutated nonsquamous non-small-cell lung cancer\n          \n          \n          2022"},{"key":"B19","unstructured":"ZEN003694 and enzalutamide versus enzalutamide monotherapy in metastatic castration-resistant prostate cancer"},{"key":"B20","unstructured":"DRP-104 in patients with NFE2L2\/KEAP1-altered non-small cell lung cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/nm.4378","article-title":"Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4","volume":"23","author":"Dai","year":"2017","journal-title":"Nat. Med."},{"key":"B22","unstructured":"WELIREG (belzutifan) tablets: prescribing information, SPL set 13e15ee0-d679-4fa9-9430-e2e2170474da\n          \n          \n          2026"},{"key":"B23","unstructured":"VEPPANU (vepdegestrant) tablets: prescribing information, SPL set 751e18d5-1d41-4b67-b1f3-10272ca5312d\n          \n          \n          2026"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/s41587-021-00857-z","article-title":"Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology","volume":"39","author":"Deveson","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41580-022-00543-1","article-title":"An expanded lexicon for the ubiquitin code","volume":"24","author":"Dikic","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1080\/10428194.2018.1466290","article-title":"Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma","volume":"60","author":"Dimopoulos","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"B27","volume-title":"BEST (Biomarkers, EndpointS, and Other Tools) Resource","year":"2016"},{"key":"B28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1128\/mcb.01191-13","article-title":"Kinetic, thermodynamic, and structural characterizations of the association between Nrf2-DLGex degron and Keap1","volume":"34","author":"Fukutomi","year":"2014","journal-title":"Mol. Cell Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/bjh.12622","article-title":"Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br. J. Haematol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.5858\/arpa.2023-0483-CP","article-title":"Principles of analytic validation of immunohistochemical assays: guideline update","volume":"148","author":"Goldsmith","year":"2024","journal-title":"Arch. Pathol. Lab. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","article-title":"Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ breast cancer models","volume":"30","author":"Gough","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"101044","DOI":"10.1016\/j.mcpro.2025.101044","article-title":"High-throughput proteomic and phosphoproteomic analysis of formalin-fixed paraffin-embedded tissues","volume":"24","author":"Haines","year":"2025","journal-title":"Mol. Cell Proteomics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"eaal3755","DOI":"10.1126\/science.aal3755","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","volume":"356","author":"Han","year":"2017","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1038\/s41467-025-59282-4","article-title":"p53 protein degradation redefines the initiation mechanisms and drives transitional mutations in colorectal cancer","volume":"16","author":"Herranz-Montoya","year":"2025","journal-title":"Nat. Commun."},{"key":"B37","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","article-title":"Targeted protein degradation for cancer therapy","volume":"25","author":"Hinterndorfer","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12915-022-01364-6","article-title":"Systematic prediction of degrons and E3 ubiquitin ligase binding via deep learning","volume":"20","author":"Hou","year":"2022","journal-title":"BMC Biol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-alpha to the von Hippel\u2013Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation","volume":"292","author":"Jaakkola","year":"2001","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nm.4372","article-title":"Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors","volume":"23","author":"Janouskova","year":"2017","journal-title":"Nat. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/1078-0432.CCR-19-1237","article-title":"Role of KEAP1\/NFE2L2 mutations in the chemotherapeutic response of patients with non-small cell lung cancer","volume":"26","author":"Jeong","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1056\/NEJMoa2504964","article-title":"Belzutifan for advanced pheochromocytoma or paraganglioma","volume":"393","author":"Jimenez","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.molcel.2018.06.036","article-title":"DUB3 promotes BET inhibitor resistance and cancer progression by deubiquitinating BRD4","volume":"71","author":"Jin","year":"2018","journal-title":"Mol. Cell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel\u2013Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/nbt.2281","article-title":"Tandem fluorescent protein timers for in vivo analysis of protein dynamics","volume":"30","author":"Khmelinskii","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1091\/mbc.E15-07-0525","article-title":"Incomplete proteasomal degradation of green fluorescent proteins in the context of tandem fluorescent protein timers","volume":"27","author":"Khmelinskii","year":"2016","journal-title":"Mol. Biol. Cell"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1093\/emboj\/18.9.2401","article-title":"An f-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin","volume":"18","author":"Kitagawa","year":"1999","journal-title":"EMBO J."},{"key":"B49","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41588-025-02496-5","article-title":"Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signaling","volume":"58","author":"Krishna","year":"2026","journal-title":"Nat. Genet."},{"key":"B50","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/j.cell.2025.02.021","article-title":"Turnover atlas of proteome and phosphoproteome across mouse tissues and brain regions","volume":"188","author":"Li","year":"2025","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.1038\/s41467-021-26871-y","article-title":"Genetic fusions favor tumorigenesis through degron loss in oncogenes","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"B53","doi-asserted-by":"publisher","first-page":"7014","DOI":"10.1038\/s41467-025-62490-7","article-title":"Author correction: genetic fusions favor tumorigenesis through degron loss in oncogenes","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"key":"B54","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nature16481","article-title":"Structure of the E6\/E6AP\/p53 complex required for HPV-mediated degradation of p53","volume":"529","author":"Martinez-Zapien","year":"2016","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.15252\/embj.201593169","article-title":"Higher-order oligomerization promotes localization of SPOP to liquid nuclear speckles","volume":"35","author":"Marzahn","year":"2016","journal-title":"EMBO J."},{"key":"B57","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41467-018-03106-1","article-title":"Systematic analysis of protein turnover in primary cells","volume":"9","author":"Mathieson","year":"2018","journal-title":"Nat. Commun."},{"key":"B58","doi-asserted-by":"publisher","first-page":"16164","DOI":"10.1074\/jbc.RA119.010596","article-title":"A robust and economical pulse-chase protocol to measure the turnover of HaloTag fusion proteins","volume":"294","author":"Merrill","year":"2019","journal-title":"J. Biol. Chem."},{"key":"B59","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41587-020-0472-9","article-title":"Multiplex digital spatial profiling of proteins and RNA in fixed tissue","volume":"38","author":"Merritt","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/nmeth.2518","article-title":"Integrated proteomic analysis of post-translational modifications by serial enrichment","volume":"10","author":"Mertins","year":"2013","journal-title":"Nat. Methods"},{"key":"B61","doi-asserted-by":"publisher","first-page":"eaak9982","DOI":"10.1126\/scisignal.aak9982","article-title":"Degrons in cancer","volume":"10","author":"M\u00e9sz\u00e1ros","year":"2017","journal-title":"Sci. Signal"},{"key":"B62","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/pros.24269","article-title":"Clinical and genomic features of SPOP-mutant prostate cancer","volume":"82","author":"Nakazawa","year":"2022","journal-title":"Prostate"},{"key":"B63","volume-title":"NCI Best Practices for Biospecimen Resources","year":"2026"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1084\/jem.20070876","article-title":"FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors","volume":"204","author":"O'Neil","year":"2007","journal-title":"J. Exp. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.euo.2023.11.014","article-title":"Co-occurring BRCA2\/SPOP mutations predict exceptional poly (ADP-ribose) polymerase inhibitor sensitivity in metastatic castration-resistant prostate cancer","volume":"7","author":"Orme","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"B66","unstructured":"Protocol C4891001, final protocol amendment 3: a phase 3, randomized, open-label, multicenter trial of ARV-471 (PF-07850327) versus fulvestrant in participants with estrogen receptor-positive, HER2-negative advanced breast cancer whose disease progressed after prior endocrine-based treatment for advanced disease (VERITAC-2) (2024). ClinicalTrials.gov identifier NCT05654623\n          \n          \n          2025"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.jmb.2015.10.002","article-title":"Multiple weak linear motifs enhance recruitment and processivity in SPOP-mediated substrate ubiquitination","volume":"428","author":"Pierce","year":"2016","journal-title":"J. Mol. Biol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41586-024-07224-3","article-title":"Proteome-scale discovery of protein degradation and stabilization effectors","volume":"628","author":"Poirson","year":"2024","journal-title":"Nature"},{"key":"B69","first-page":"765","article-title":"Somatic inactivation of the VHL gene in Von Hippel\u2013Lindau disease tumors","volume":"60","author":"Prowse","year":"1997","journal-title":"Am. J. Hum. Genet."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1128\/MCB.01204-10","article-title":"SCF\/\u03b2-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner","volume":"31","author":"Rada","year":"2011","journal-title":"Mol. Cell Biol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","article-title":"Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma","volume":"389","author":"Richardson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-19-3387","article-title":"A randomized, open-label, presurgical, window-of-opportunity study comparing the pharmacodynamic effects of the novel oral SERD AZD9496 with fulvestrant in patients with newly diagnosed ER-positive HER2-negative primary breast cancer","volume":"26","author":"Robertson","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaw1219","article-title":"Slide-seq: a scalable technology for measuring genome-wide expression at high spatial resolution","volume":"363","author":"Rodriques","year":"2019","journal-title":"Science"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/nm.4407","article-title":"Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis","volume":"23","author":"Romero","year":"2017","journal-title":"Nat. Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"100016","DOI":"10.1074\/mcp.R120.002190","article-title":"Proteome turnover in the spotlight: approaches, applications, and perspectives","volume":"20","author":"Ross","year":"2021","journal-title":"Mol. Cell Proteomics"},{"key":"B77","doi-asserted-by":"publisher","first-page":"100760","DOI":"10.1016\/j.crmeth.2024.100760","article-title":"Systematic analysis of proteome turnover in an organoid model of pancreatic cancer by dSILO","volume":"4","author":"Ross","year":"2024","journal-title":"Cell Rep. Methods"},{"key":"B78","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.cell.2018.02.030","article-title":"Multiplexed proteome dynamics profiling reveals mechanisms controlling protein homeostasis","volume":"173","author":"Savitski","year":"2018","journal-title":"Cell"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/0092-8674(90)90409-8","article-title":"The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53","volume":"63","author":"Scheffner","year":"1990","journal-title":"Cell"},{"key":"B80","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41467-023-44237-4","article-title":"DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance","volume":"15","author":"Schr\u00f6der","year":"","journal-title":"Nat. Commun."},{"key":"B81","doi-asserted-by":"publisher","first-page":"7109","DOI":"10.1038\/s41467-024-51317-6","article-title":"Author correction: DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance","volume":"15","author":"Schr\u00f6der","year":"","journal-title":"Nat. Commun."},{"key":"B82","doi-asserted-by":"publisher","first-page":"13568","DOI":"10.1073\/pnas.0806268105","article-title":"Cancer Related Mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy","volume":"105","author":"Shibata","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B83","doi-asserted-by":"publisher","first-page":"10392","DOI":"10.1073\/pnas.0905305106","article-title":"Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy","volume":"106","author":"Shibata","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e2501243","DOI":"10.1200\/PO-25-01243","article-title":"Generic protocols for the analytical validation of next-generation sequencing-based circulating tumor DNA assays, version 2.0","volume":"10","author":"Silvestro","year":"2026","journal-title":"JCO Precis. Oncol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"e420","DOI":"10.1371\/journal.pmed.0030420","article-title":"Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer","volume":"3","author":"Singh","year":"2006","journal-title":"PLoS Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","article-title":"CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors","volume":"635","author":"Skoulidis","year":"2024","journal-title":"Nature"},{"key":"B87","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.1038\/s41586-025-08767-9","article-title":"Author correction: CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors","volume":"639","author":"Skoulidis","year":"2025","journal-title":"Nature"},{"key":"B88","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nmeth.4380","article-title":"Simultaneous epitope and transcriptome measurement in single cells","volume":"14","author":"Stoeckius","year":"2017","journal-title":"Nat. Methods"},{"key":"B89","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1093\/emboj\/19.16.4298","article-title":"Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel\u2013Lindau tumor suppressor protein","volume":"19","author":"Tanimoto","year":"2000","journal-title":"EMBO J."},{"key":"B90","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.1250255","article-title":"Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer","volume":"346","author":"Theurillat","year":"2014","journal-title":"Science"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.molcel.2021.01.020","article-title":"Systematic characterization of mutations altering protein degradation in human cancers","volume":"81","author":"Tokheim","year":"2021","journal-title":"Mol. Cell"},{"key":"B92","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1128\/mcb.26.8.2887-2900.2006","article-title":"Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model","volume":"26","author":"Tong","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"7511","DOI":"10.1128\/mcb.00753-07","article-title":"Different electrostatic potentials define ETGE and DLG motifs as Hinge and latch in oxidative stress response","volume":"27","author":"Tong","year":"2007","journal-title":"Mol. Cell Biol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","article-title":"Targeted protein degradation: from mechanisms to clinic","volume":"25","author":"Tsai","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s44318-024-00289-w","article-title":"Towards routine proteome profiling of FFPE tissue: insights from a 1,220-case pan-cancer study","volume":"44","author":"T\u00fcshaus","year":"2025","journal-title":"EMBO J."},{"key":"B96","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1074\/mcp.M111.016857","article-title":"Methods for quantification of in vivo changes in protein ubiquitination following proteasome and deubiquitinase inhibition","volume":"11","author":"Udeshi","year":"2012","journal-title":"Mol. Cell Proteomics"},{"key":"B97","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1074\/mcp.O112.027094","article-title":"Refined preparation and use of anti-diglycine remnant (K-\u03b5-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments","volume":"12","author":"Udeshi","year":"2013","journal-title":"Mol. Cell Proteomics"},{"key":"B98","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nchembio.2363","article-title":"Selective degradation of splicing factor CAPER\u03b1 by anticancer sulfonamides","volume":"13","author":"Uehara","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"B99","volume-title":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","year":"2026"},{"key":"B100","unstructured":"FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer\n          \n          \n          2026"},{"key":"B101","volume-title":"In vitro","year":"2014"},{"key":"B102","volume-title":"Qualifying a Biomarker Through the Biomarker Qualification Program","year":"2018"},{"key":"B110","article-title":"Enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products","year":"2019","journal-title":"Final Guid. March 2019. Docket No. FDA-2012-D-1145"},{"key":"B103","unstructured":"Guardant360 CDx PMA supplement P200010\/S010: summary of safety and effectiveness data for plasma ESR1 testing with elacestrant"},{"key":"B104","unstructured":"FDA approves belzutifan for advanced renal cell carcinoma"},{"key":"B105","unstructured":"FDA approves belzutifan for pheochromocytoma or paraganglioma"},{"key":"B106","unstructured":"FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma"},{"key":"B107","unstructured":"List of FDA-authorized companion diagnostic devices (in vitro and imaging tools)"},{"key":"B108","unstructured":"Guardant360 CDx PMA supplement P200010\/S025 for ESR1 mutation selection with vepdegestrant"},{"key":"B109","volume-title":"Vepdegestrant NDA 219835 Multidisciplinary Review","year":""},{"key":"B111","article-title":"Von Hippel\u2013Lindau syndrome","volume-title":"Genereviews\u00ae","author":"van Leeuwaarde","year":"2025"},{"key":"B112","doi-asserted-by":"publisher","first-page":"eadz3483","DOI":"10.1126\/sciadv.adz3483","article-title":"A near-complete map of human cytosolic degrons and their relevance for disease","volume":"12","author":"Voutsinos","year":"2026","journal-title":"Sci. Adv."},{"key":"B113","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41589-025-02056-2","article-title":"Degrons and degradation signals beyond short linear motifs","volume":"22","author":"Wang","year":"2026","journal-title":"Nat. Chem. Biol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1126\/science.add7574","article-title":"Molecular glue CELMoD compounds are regulators of cereblon conformation","volume":"378","author":"Watson","year":"2022","journal-title":"Science"},{"key":"B115","doi-asserted-by":"publisher","first-page":"9085","DOI":"10.1073\/pnas.0402770101","article-title":"The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation","volume":"101","author":"Welcker","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B116","doi-asserted-by":"publisher","first-page":"eabl7872","DOI":"10.1126\/sciadv.abl7872","article-title":"Two diphosphorylated degrons control c-Myc degradation by the Fbw7 tumor suppressor","volume":"8","author":"Welcker","year":"2022","journal-title":"Sci. Adv."},{"key":"B117","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1038\/sj.emboj.7600217","article-title":"Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7","volume":"23","author":"Yada","year":"2004","journal-title":"EMBO J."},{"key":"B118","doi-asserted-by":"publisher","first-page":"10941","DOI":"10.1128\/mcb.24.24.10941-10953.2004","article-title":"Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex","volume":"24","author":"Zhang","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/nm.4379","article-title":"Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation","volume":"23","author":"Zhang","year":"2017","journal-title":"Nat. Med."},{"key":"B120","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41580-025-00870-z","article-title":"Degrons: defining the rules of protein degradation","volume":"26","author":"Zhang","year":"2025","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"bbae519","DOI":"10.1093\/bib\/bbae519","article-title":"MetaDegron: multimodal feature-integrated protein language model for predicting E3 ligase targeted degrons","volume":"25","author":"Zheng","year":"2024","journal-title":"Brief. Bioinform"},{"key":"B122","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","article-title":"Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma","volume":"124","author":"Zhu","year":"2014","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41408-019-0173-0","article-title":"Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4","volume":"9","author":"Zhu","year":"2019","journal-title":"Blood Cancer J."},{"key":"B124","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.cell.2024.11.010","article-title":"Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer","volume":"188","author":"Zucker","year":"2025","journal-title":"Cell"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1960932\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:09:08Z","timestamp":1790320148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1960932\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":124,"alternative-id":["10.3389\/fcell.2026.1960932"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1960932","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1960932"}}